Racial differences in real-world outcomes of first-line therapies for advanced renal cell carcinoma.

ABSTRACT:

Background

Given the historical underrepresentation of racial minorities in clinical trials, little is known about racial differences in outcomes of first-line therapies for advanced renal cell carcinoma (aRCC). This study described patient characteristics and clinical outcomes of first-line therapies for aRCC, including nivolumab + ipilimumab, pembrolizumab + axitinib, and tyrosine kinase inhibitors, by race in the real-world setting.

Methods

We conducted a retrospective medical chart review of patients with intermediate/poor-risk clear-cell aRCC. Treating physicians abstracted patient data from electronic medical charts.

Results

Among 346 patients with intermediate/poor-risk aRCC, a higher proportion of African-American/Black (n = 78) versus White (n = 268) patients

SUBMITTER: Geynisman DM 

PROVIDER: S-EPMC12311295 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature